<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00471484</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000543536</org_study_id>
    <secondary_id>SINGAPORE-OC-GI-01-06</secondary_id>
    <secondary_id>SINGAPORE-IRB-06-16-HEP</secondary_id>
    <secondary_id>SINGAPORE-CTC0600327</secondary_id>
    <secondary_id>SPRI-SINGAPORE-OC-GI-01-06</secondary_id>
    <nct_id>NCT00471484</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy and Interferon Alfa-2b in Treating Patients With Nonmetastatic Liver Cancer That Cannot Be Removed by Surgery</brief_title>
  <official_title>A Phase II Trial of Oxaliplatin/Adriamycin/5 Fluorouracil in Continuous Infusion / Interferon α-2b (OXAFI) Combination as Neoadjuvant Therapy in Unresectable Non-Metastatic Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as oxaliplatin, doxorubicin, and fluorouracil,&#xD;
      work in different ways to stop the growth of tumor cells, either by killing the cells or by&#xD;
      stopping them from dividing. Interferon alfa may interfere with the growth of tumor cells.&#xD;
      Giving combination chemotherapy together with interferon alfa may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving combination chemotherapy together&#xD;
      with interferon alfa-2b works in treating patients with nonmetastatic liver cancer that&#xD;
      cannot be removed by surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the response rate in patients with unresectable, nonmetastatic hepatocellular&#xD;
           carcinoma treated with neoadjuvant oxaliplatin, doxorubicin hydrochloride, fluorouracil,&#xD;
           and recombinant interferon alfa-2b.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the overall survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the progression-free survival of patients treated with this regimen.&#xD;
&#xD;
        -  Determine the rate of conversion to resectability of tumor in patients treated with this&#xD;
           regimen.&#xD;
&#xD;
        -  Determine the toxicity profile of this regimen in these patients.&#xD;
&#xD;
        -  Assess the quality of life of patients treated with this regimen.&#xD;
&#xD;
        -  Correlate changes in serological markers of angiogenesis before and after treatment with&#xD;
           clinical outcome in these patients.&#xD;
&#xD;
        -  Correlate and validate the use of functional imaging before and after treatment with&#xD;
           clinical outcome in these patients.&#xD;
&#xD;
      OUTLINE: Patients receive neoadjuvant OXAFI therapy comprising oxaliplatin IV and doxorubicin&#xD;
      hydrochloride IV on days 1, 8 and 15; fluorouracil IV continuously on days 1-28; and&#xD;
      recombinant interferon alfa-2b subcutaneously three times weekly in weeks 1-4. Treatment&#xD;
      repeats every 28 days for up to 6 courses in the absence of disease progression or&#xD;
      unacceptable toxicity. Patients receive at least 2 courses of neoadjuvant therapy before&#xD;
      undergoing evaluation for response. Patients whose disease becomes resectable after achieving&#xD;
      a complete or partial response proceed to surgery. Patients whose disease remains&#xD;
      unresectable are reevaluated until their disease either becomes resectable, they complete&#xD;
      neoadjuvant therapy, or they meet discontinuation criteria.&#xD;
&#xD;
      At least 2 weeks after receiving neoadjuvant therapy, patients whose disease is resectable&#xD;
      undergo surgery for potentially complete resection of their tumors with curative intent.&#xD;
      Patients who achieve complete resection proceed to adjuvant therapy.&#xD;
&#xD;
      At least 4 weeks after surgery, patients may restart OXAFI as adjuvant therapy, provided they&#xD;
      have fully recovered from surgery and have received fewer than 6 courses of neoadjuvant&#xD;
      therapy. Adjuvant therapy repeats every 28 days for a total of 6 courses (including&#xD;
      neoadjuvant OXAFI) in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood and tissue collection at baseline and periodically during study for&#xD;
      evaluation of circulating and tissue biomarkers of angiogenesis. Serum from venous blood&#xD;
      samples is analyzed for concentration of VEGF by ELISA. Tumor tissue obtained before and&#xD;
      after treatment is examined for tumor VEGF expression, microvessel density, and cellular&#xD;
      proliferation by IHC.&#xD;
&#xD;
      Patients complete quality of life questionnaires at baseline, monthly during study treatment,&#xD;
      after course 6 of neoadjuvant chemotherapy, or upon discontinuation of study treatment.&#xD;
&#xD;
      Patients are followed periodically for up to 5 years after curative resection of their&#xD;
      tumors.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 54 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2007</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective tumor response rate as measured by RECIST criteria</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum VEGF levels</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue VEGF expression</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Liver Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>recombinant interferon alfa-2b</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxaliplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diagnostic laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>adjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>biopsy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>therapeutic conventional surgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed hepatocellular carcinoma&#xD;
&#xD;
               -  Advanced, unresectable, nonmetastatic disease&#xD;
&#xD;
               -  Multifocal disease within the same lobe of the liver allowed&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by&#xD;
             conventional techniques or ≥ 10 mm by spiral CT scan&#xD;
&#xD;
          -  No intractable ascites that cannot be controlled by medical therapy&#xD;
&#xD;
          -  No extrahepatic metastases&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  WBC ≥ 3,000/mm³&#xD;
&#xD;
          -  ANC ≥ 1,500/mm³&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm³&#xD;
&#xD;
          -  Hemoglobin ≥ 9 g/dL&#xD;
&#xD;
          -  Bilirubin ≤ 2.9 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 5 times upper reference range (URR)&#xD;
&#xD;
          -  Albumin &gt; 30 g/L&#xD;
&#xD;
          -  Creatinine ≤ 1.5 times URR&#xD;
&#xD;
          -  Creatinine clearance &gt; 50 mL/min&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 6 months after&#xD;
             completion of study therapy&#xD;
&#xD;
          -  No other prior malignancy except nonmelanoma skin cancer or carcinoma in situ of the&#xD;
             cervix&#xD;
&#xD;
          -  No concurrent substantial medical illness, such as cardiac or renal disease&#xD;
&#xD;
          -  MUGA heart study normal&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition used in the study&#xD;
&#xD;
          -  No history of autoimmune disease&#xD;
&#xD;
          -  No thyroid dysfunction&#xD;
&#xD;
          -  No active hepatitis B or C flare or chronic active hepatitis&#xD;
&#xD;
          -  Hepatitis B surface antigen (HBsAg) status known&#xD;
&#xD;
               -  If HBsAg is negative, anti-HBc antibodies should be tested; if anti-HBc is&#xD;
                  positive, then hepatitis B virus (HBV) DNA detection should be performed to&#xD;
                  discern presence of mutant HBV carriage&#xD;
&#xD;
          -  No alcohol or drug abuse&#xD;
&#xD;
          -  No concurrent uncontrolled illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Ongoing or active infection&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
               -  Patients with a history of depression or psychiatric disorders are ineligible&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior chemotherapy and/or radiotherapy&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Poon, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kian Fong Foo, MD</last_name>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donald Poon, MD</last_name>
      <phone>65-6-436-8000</phone>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <results_reference>
    <citation>Ang MK, Poon D, Foo KF, Chung YF, Chow P, Wan WK, Thng CH, Ooi L. A new chemoimmunotherapy regimen (OXAFI) for advanced hepatocellular carcinoma. Hematol Oncol Stem Cell Ther. 2008 Jul-Sep;1(3):159-65.</citation>
    <PMID>20063546</PMID>
  </results_reference>
  <verification_date>November 2008</verification_date>
  <study_first_submitted>May 8, 2007</study_first_submitted>
  <study_first_submitted_qc>May 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2007</study_first_posted>
  <last_update_submitted>June 21, 2011</last_update_submitted>
  <last_update_submitted_qc>June 21, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2011</last_update_posted>
  <keyword>adult primary hepatocellular carcinoma</keyword>
  <keyword>localized unresectable adult primary liver cancer</keyword>
  <keyword>advanced adult primary liver cancer</keyword>
  <keyword>childhood hepatocellular carcinoma</keyword>
  <keyword>stage III childhood liver cancer</keyword>
  <keyword>stage IV childhood liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Interferon alpha-2</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

